Skip to content

Effect of folic acid, vitamin E, selenium on semen parameters

The effects of folic acid, vitamin E, selenium on semen parameters in infertile men

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017012432153N1
Enrollment
Unknown
Registered
2017-06-17
Start date
2017-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

male infertility. Azoospermia NOS - Oligospermia NOS

Interventions

Placebo
Intervention 1: Intervention group:Daily intake of 200 micrograms of selenium tablets nature med Manufacturing Co., 400 IU of vitamin zahravi Manufacturing Co. i, 5 mg folic acid tablets Galinuse Man
Treatment - Drugs
Intervention group:Daily intake of 200 micrograms of selenium tablets nature med Manufacturing Co., 400 IU of vitamin zahravi Manufacturing Co. i, 5 mg folic acid tablets Galinuse Manufacturing Co.
control group:Placebo daily for 12 weeks

Sponsors

Vice Chancellor for research of Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
25 Years to 54 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Tendency to participate in the study; Age range 25 to 54 years; Do not use of micronutrients out of study; Rejection of any obstructive disorder during radiological studies and anatomical examination; Abnormal parametres be approved by two semen analysis within two weeks exclusion criteria: lake of Tendency to participate in the study; Azoospermia or Aspermia men; Men with sever varicocele; Recent urogenital infection that have been treated with antioxidants; History of allergic reactions to micronutrients; treated with the following drugs: sulfasalazine- methotrexate-Nitrofurantoin -colchicine –alpha blockers and cimetidine - spironolactone-antidepressants, beta-blocker-phenothiazine-metoclopramide-heroin- cocaine-cannabis-thiazide diuretic

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Sperm morphology. Timepoint: Before intervention ninety days after intervention. Method of measurement: semenal analysis.;Sperm count. Timepoint: Before and ninety days after intervention. Method of measurement: semenal analysis.;Sperm motility. Timepoint: Before and ninety days after intervention. Method of measurement: semenal analysis.;White blood cell count. Timepoint: Before and ninety days after intervention. Method of measurement: semenal analysis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzima Sara

School of Nursing and Midwifery, Shiraz

azimas@sums.ac.ir+98 71 3647 4254

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 16, 2026